ClinicalTrials.gg
Sign In

Drug

ZEN-3694 clinical trials

Also written ZEN003694 and ZEN-3694.

studies test it
15
open now
10
in phase 3
0
first study started
2016

Keep track of what changes. Save the ZEN-3694 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

BET Bromodomain Inhibitor ZEN-3694
8
BETi ZEN-3694
8

Development codes

ZEN003694
15
ZEN-3694
9

Studies by the year they started

15 studies that test it; most in 2022 (4)

Studies that test ZEN-3694, by start year
YearStudies
20162
20191
20212
20224
20234
20242

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
8

What it is tested for

Each study’s main condition, where its own words name it.

Prostatic Neoplasms
3
Colorectal Neoplasms
2
Endometrial Neoplasms
1
Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1

Who runs them

Industry 4 · Other 11

National Cancer Institute (NCI) (7) · Zenith Epigenetics (4) · Rahul Aggarwal (1) · Memorial Sloan Kettering Cancer Center (1) · Alexander B Olawaiye, MD (1) · Haider Mahdi (1)

Often tested with

Tested in the same studies.

Talazoparib (2) · Enzalutamide (2) · Pembrolizumab (1) · Tuvusertib (1) · Binimetinib (1) · Capecitabine (1) · Cetuximab (1) · Encorafenib (1)

Studies

Open first, then newest update. How each study uses ZEN-3694 is read from its arms, and is right about nine times in ten.

Testing it · 15

Given in every arm · 5 — ZEN-3694 is usual care beside what is tested

Codes

What other systems call ZEN-3694 · ClinicalTrials.gg INT017443

  • UNII (FDA) O28XHZ9UQ4ZEN-3694One source FDA
  • NCI Thesaurus C126805BET Bromodomain Inhibitor ZEN-3694One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.